Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US
Lytix Biopharma today announce that the US Patent Office has granted two patents in the US and covering the use of its leading product candidate LTX-315 in combination with chemotherapeutic agents US (11123398) and with the checkpoint inhibitor anti-CTLA-4 (US 11083774).
“We are very satisfied with the success of our patent prosecution related to our patent families in the US, the most important market world-wide for pharmaceutical products. These grants highlight the novelty of our therapy and further strengthens our business case as securing intellectual property rights is of critical importance for the protection of Lytix' technology platform and the long-term value generation of the company,” says Dr. Øystein Rekdal, CEO of Lytix Biopharma.
In July 2021, Lytix Biopharma announced the official opening of a Phase II combination study in the US with LTX-315 and the immune checkpoint inhibitor Pembrolizumab, which blocks tumor cells’ ability to inhibit the body’s immune response, in patients with solid tumors. Results from earlier-initial studies indicate that the combination of LTX-315 and Pembrolizumab may work better than Pembrolizumab alone. The trial will be a multicenter study including MD Anderson Cancer Center in Texas, which is one of the world leading cancer hospitals.